NAMPT抑制劑市場 - 開發平台分析 - 全球產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)

本報告提供全球NAMPT抑制劑市場相關調查，提供市場概要，以及2022年～2031年的預測，各相，各用途，各分子類型，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 前提與調查手法

第3章 摘要整理:全球NAMPT抑制劑市場

第4章 市場概要

• 簡介
• 概要
• 市場動態
  • 促進因素
  • 阻礙因素
  • 機會

第5章 主要洞察

第6章 北美的NAMPT抑制劑市場分析與預測

• 簡介
  • 主要調查結果
• 市場分析，各相，2017年～2031年
  • 第二階段
  • 第一/二階段
  • 第一階段
  • 前臨床
• 市場分析，各用途，2017年～2031年
  • 腫瘤學
  • 其他(呼吸系統·神經疾病)
• 市場分析，各分子類型，2017年～2031年
  • 低分子
  • 生技藥品

第7章 歐洲的NAMPT抑制劑市場分析與預測

第8章 其他地區的NAMPT抑制劑市場分析與預測

第9章 競爭情形

• 市場參與企業-競爭矩陣(各等級及各企業規模)
• 企業簡介
  • Onxeo
  • Aqualung Therapeutics
  • Antengene Corporation
  • OncoTartis, Inc.
  • Karyopharm Therapeutics

TMR's report on the global NAMPT inhibitors pipeline analysis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global NAMPT inhibitors pipeline analysis market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global NAMPT inhibitors pipeline analysis market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the NAMPT inhibitors pipeline analysis market.

The report delves into the competitive landscape of the global NAMPT inhibitors pipeline analysis market. Key players operating in the global NAMPT inhibitors pipeline analysis market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global NAMPT inhibitors pipeline analysis market profiled in this report.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global NAMPT Inhibitors Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Phase Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities

5. Key Insights

• 5.1. Overview on Kay players operating in the market space
• 5.2. Key industry events (mergers, acquisitions, partnerships, etc.)
• 5.3. COVID-19 pandemic impact on industry

6. North America NAMPT Inhibitors Market Analysis and Forecast

• 6.1. Introduction
  • 6.1.1. Key Findings
• 6.2. Market Analysis, by Phase, 2017 - 2031
  • 6.2.1. Phase II
  • 6.2.2. Phase I/II
  • 6.2.3. Phase I
  • 6.2.4. Preclinical
• 6.3. Market Analysis, by Application, 2017 - 2031
  • 6.3.1. Oncology
  • 6.3.2. Others (respiratory and neurology disorders)
• 6.4. Market Analysis, by Type of Molecule, 2017 - 2031
  • 6.4.1. Small Molecules
  • 6.4.2. Biologics

7. Europe NAMPT Inhibitors Market Analysis and Forecast

• 7.1. Introduction
  • 7.1.1. Key Findings
• 7.2. Market Analysis, by Phase, 2017 - 2031
  • 7.2.1. Phase II
  • 7.2.2. Phase I/II
  • 7.2.3. Phase I
  • 7.2.4. Preclinical
• 7.3. Market Analysis, by Application, 2017 - 2031
  • 7.3.1. Oncology
  • 7.3.2. Others (Respiratory and Neurology Disorders)
• 7.4. Market Analysis, by Type of Molecule, 2017 - 2031
  • 7.4.1. Small Molecules
  • 7.4.2. Biologics

8. Rest of the World NAMPT Inhibitors Market Analysis and Forecast

• 8.1. Introduction
  • 8.1.1. Key Findings
• 8.2. Market Analysis, by Phase, 2017 - 2031
  • 8.2.1. Phase II
  • 8.2.2. Phase I/II
  • 8.2.3. Phase I
  • 8.2.4. Preclinical
• 8.3. Market Analysis, by Application, 2017 - 2031
  • 8.3.1. Oncology
  • 8.3.2. Others (Respiratory and Neurology Disorders)
• 8.4. Market Analysis, by Type of Molecule, 2017 - 2031
  • 8.4.1. Small Molecules
  • 8.4.2. Biologics

9. Competition Landscape

• 9.1. Market Player - Competition Matrix (by tier and size of companies)
• 9.2. Company Profiles
  • 9.2.1. Onxeo
    • 9.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 9.2.1.2. Product Portfolio
    • 9.2.1.3. SWOT Analysis
    • 9.2.1.4. Strategic Overview
  • 9.2.2. Aqualung Therapeutics
    • 9.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 9.2.2.2. Product Portfolio
    • 9.2.2.3. SWOT Analysis
    • 9.2.2.4. Strategic Overview
  • 9.2.3. Antengene Corporation
    • 9.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 9.2.3.2. Product Portfolio
    • 9.2.3.3. SWOT Analysis
    • 9.2.3.4. Strategic Overview
  • 9.2.4. OncoTartis, Inc.
    • 9.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 9.2.4.2. Product Portfolio
    • 9.2.4.3. SWOT Analysis
    • 9.2.4.4. Strategic Overview
  • 9.2.5. Karyopharm Therapeutics
    • 9.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 9.2.5.2. Product Portfolio
    • 9.2.5.3. SWOT Analysis
    • 9.2.5.4. Strategic Overview